BusinessCeltaxsys announces the issue of four new patents expanding its pipeline of selective leukotriene B4 modulation anti-inflammatory medicinesBy Nasdaq OMXFeb 1, 2018, 1:00 PM UTC
BusinessCeltaxsys Secures Private Financing to Advance Acebilustat Phase 3 Cystic Fibrosis (CF) Program Preparatory ActivitiesBy Nasdaq OMXJan 4, 2018, 1:02 PM UTC
BusinessProQR to Present at the Annual Piper Jaffray Healthcare ConferenceBy Nasdaq OMXNov 21, 2017, 12:00 PM UTC
BusinessAnthera Pharmaceuticals Announces Completion of Recruitment in the Phase 3 RESULT Clinical Study of SollpuraBy Nasdaq OMXNov 9, 2017, 1:30 PM UTC
BusinessThrive Event Raises Over $150K for Claire’s Place FoundationBy Nasdaq OMXNov 8, 2017, 2:01 PM UTC
BusinessAnthera Pharmaceuticals Announces Presentation of Blisibimod Data at the American College of Rheumatology Annual MeetingBy Nasdaq OMXNov 5, 2017, 1:30 PM UTC
BusinessAnthera Pharmaceuticals Announces Presentations of Sollpura Data at the North American Cystic Fibrosis ConferenceBy Nasdaq OMXNov 2, 2017, 12:30 PM UTC
BusinessAnthera Pharmaceuticals Announces Presentation of Blisibimod Lupus Research at the American Society of Nephrology Annual MeetingBy Nasdaq OMXNov 1, 2017, 9:00 PM UTC
